SCGB1A1 and acute respiratory distress syndrome: This hypothesis is supported by previous studies indicating the efficacy of recombinant CC10 protein treatment in ameliorating lung function and moderating inflammatory responses in various animal models, including COPD [29], acute respiratory distress syndrome [30], and allergic rhinitis [31].